404 results about "Auto immune" patented technology

The invention relates to the technical field of microorganisms, in particular to a bifidobacterium animalis subsp. Lactis and application thereof, and particularly provides a bifidobacterium animalis subsp. Lactis BX-BC08 which is beneficial for restoring the microecological balance of the intestinal tract and enhancing the immune barrier function of the intestinal tract. Experiments prove that the bifidobacterium animalis subsp. Lactis BX-BC08 disclosed by the invention can regulate an immune system and relieve excessive immune response, can reduce generation of inflammatory factors and relieve skin inflammation symptoms for autoimmune related diseases such as atopic dermatitis, is relatively good in tolerance to a human body, and greatly reduces adverse reaction of the human body.

The invention discloses an OTX-015 (Ox-015) loaded cascaded responsive nano particle and a preparation method thereof. The nanoparticle has a three-layer core-shell structure, wherein the innermost layer is a cross-linked nanoparticle of chitosan and paclitaxel; the middle layer is a polydopamine layer loaded with a bromodomain inhibitor OTX-015; the outermost layer is a gelatin layer grafted with babali; wherein the cross-linked substance of the chitosan and the paclitaxel is a cross-linked substance containing a disulfide bond. The invention also provides a preparation method of the cascade responsive nano-particle and application of the cascade responsive nano-particle in preparation of an antitumor drug targeted delivery system. The nanoparticle provided by the invention improves the tumor microenvironment while activating in-vivo autoimmunity, and kills tumor cells by using photothermal therapy assisted chemotherapy drugs, so that the synergistic effect of chemotherapy / photothermal therapy / immunotherapy is realized, and a new idea is provided for clinical tumor treatment.

The invention provides a complementary determining region 3 and immune epitope binding prediction method, and belongs to the field of bioinformatics. According to the method, multi-modal heterogeneous graph modeling, a graph attention network (GAT) and multi-objective loss function collaborative optimization are fused, and the method aims at breaking through the limitation of the prior art in the aspects of heterogeneous data modeling, class imbalance, prediction precision and the like. A heterogeneous graph of 3 nodes of a complementary determining region and immune epitope nodes is constructed, GAT is introduced to realize cross-modal feature interaction, and a dynamic weight optimization strategy of a focus loss function and an AUC loss function is combined, so that the recognition capability and the overall sorting performance of the model on difficult samples are improved. And meanwhile, interpretable analysis combined with the hotspot residues is realized through the attention weight. According to the method, the prediction accuracy of the binding specificity of the complementarity determining region 3 and the immune epitope is remarkably improved, and the method can be widely applied to cancer vaccine design, individualized immunotherapy and autoimmune disease research and has important theoretical significance and practical application value.

The invention relates to a pyrimidopyrrole derivative and application thereof in medicine, in particular to a compound shown in a general formula (I) or a stereoisomer, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal of the compound, an intermediate and a preparation method of the compound, and application of the compound in BTK related diseases such as tumors or autoimmune system diseases. # imgabs0 #

The invention discloses an arabidopsis thaliana RK3 gene and application of S structural domain receptor kinase RK3 coded by the arabidopsis thaliana RK3 gene in improvement of plant disease resistance, and belongs to the technical field of plant genetic engineering. According to the application of the arabidopsis thaliana RK3 gene to improvement of plant disease resistance, the nucleotide sequence of the arabidopsis thaliana RK3 gene is shown as SEQ ID NO.1, the amino acid sequence of S structural domain receptor kinase RK3 coded by the arabidopsis thaliana RK3 gene is shown as SEQ ID NO.2, and further plants are selected from arabidopsis thaliana, oilseed rape, rice, tomatoes, potatoes, peanuts, soybeans, cotton, tobacco, cucumbers, watermelons and the like. The expression of the plant disease resistance comprises infection resistance to wild-type pseudomonas syringae, effector engineering strains thereof and botrytis cinerea. It is clear that the arabidopsis thaliana RK3 gene and the encoded protein thereof can remarkably enhance the infection resistance of plants to various pathogenic bacteria for the first time, disease prevention and control are achieved by activating the autoimmune system of the plants, and an effective path is provided for reducing chemical pesticide application and promoting agricultural green development.

The invention discloses a chimera for degrading a CARD structural domain protein aggregate and application of the chimera. The chimera is prepared from light-operated targeting protein and light-operated degradation protein, the light-operated targeting protein is sequentially connected by an MAVS CARD structural domain, a flexible connecting peptide and a photosensitive protein pMag; the light-controlled degradation protein is sequentially connected by a photosensitive protein nMag, a flexible connecting peptide and an RING structural domain of TRIM21. According to the application, a light-operated activated CARD-RING chimera is constructed, and when the CARTAC generates toxic and side effects or in cells with RIG-I / MDA5 signal channels abnormally activated, the activity of the CARTAC can be effectively controlled or autoimmune diseases caused by RIG-I / MDA5 abnormity can be inhibited.

The present invention provides EGFR and c-MET bispecific antibodies, antigen binding portions thereof, other binding agents and EGFR and c-MET bispecific conjugates thereof, as well as methods and uses of such antibodies and conjugates for the treatment of cancer and autoimmune disease.

The invention belongs to the field of new application of medicines, and particularly relates to application of SIRT4-IN-1 in preparation of medicines for treating autoimmune diseases. It is found for the first time that SIRT4-IN-1 reduces the activation degree of immune response induced by HSV-1 virus infection by up-regulating acetylation modification of cGAS, inhibits abnormal activation of immune response in Trex1 deficient mouse cells and peripheral blood mononuclear cells of systemic lupus erythematosus patients, and improves abnormal activation of autoimmune response. The invention provides a new candidate drug for clinical treatment of systemic lupus erythematosus.

Methods and systems for detecting one or more autoantibodies and / or analytes associated with one or more clinical feature or outcome, such as an autoimmune and related disease or other disease through binding events on a biomolecule array. Kinetic parameters of the binding events can be determined. The kinetic parameters may be used to identify one or more clinical feature or outcome, such as diagnose one or more disease, such as an autoimmune and related disease, and / or to provide a prognosis of one or more disease. The kinetic parameters may be used as inputs in one or more machine learning algorithms to identify associations and / or correlations between one or more kinetic parameter and / or other additional information and one or more clinical feature or outcome.

The invention discloses a preparation method of a stem cell exosome chitosan compound covered stent. The stem cell exosome chitosan compound comprises a stem cell exosome and a chitosan compound. In the stem cell exosome and chitosan compound, the mass percent of chitosan is 3%-10%, and the number of the stem cell exosomes is 109-1011. Compared with a traditional covered stent, the covered material provided by the invention can resist inflammation, inhibit bacteria, protect vascular endothelial cells covered by the stent, promote tissue repair, prevent tissue adhesion, prevent fibrosis and inhibit exclusion reaction and autoimmunity.

Provided here are methods to prevent, inhibit or treat an autoimmune disease or a vascular or cardiovascular disorder in a mammal, comprising administering to the mammal a composition comprising an effective amount of isolated nucleic acid comprising a nucleotide sequence encoding WDFY3 / Alfy or a portion thereof, a nucleotide sequence comprising a WDFY3 / Alfy-specific long non-coding RNA (lncRNA) or a corresponding DNA sequence, a nucleotide sequence comprising a portion of a lncRNA WDFY3-AS2 or a corresponding DNA sequence, or isolated WDFY3 / Alfy or a portion thereof.

Provided herein are antibodies and antibody fragments that bind to human TNFRSF25. The antibodies may be monoclonal and / or biparatopic antibodies and / or single- chain fragment variable (scFv) antibodies. Methods of treating or preventing diseases or disorders associated with inflammation and / or autoimmunity are provided, comprising administering to a patient in need thereof an effective amount of a human TNFRSF25- binding antibody.

Provided herein are systems and methods for identifying a disease or disorder of a patient, identifying if a patient is likely to respond to a treatment for the disease or disorder, and / or predicting the clinical outcome of the disease or disorder of a patient. Systems and methods described herein may be directed to patients with different chronic conditions, inflammatory conditions, and / or autoimmune conditions. Systems and methods described herein may be directed to patients with a dermatological condition.

Provided herein are compositions and methods for the treatment of an autoimmune or inflammatory disease, such as rheumatoid arthritis. Said compositions comprise a TNFR1 inhibitor. Some embodiments comprise combination therapy featuring the TNFR1 inhibitor with at least one additional anti-inflammatory therapeutic agent.

The invention belongs to the technical field of immunology, and particularly discloses an in-vitro preparation method and application of an induced follicular regulatory T cell iTfr.The in-vitro preparation method comprises the steps that mouse spleen single-cell suspension or healthy human peripheral blood is obtained, peripheral blood mononuclear cells are obtained, then initial CD4 + T cells are obtained through immunomagnetic bead sorting, and iTfr cells are obtained; then carrying out induced differentiation by using an antibody and a specific cytokine, and carrying out continuous stimulation and culture by adopting two different cytokine polarization conditions, so as to obtain the iTfr cell. The invention provides a method for preparing the iTfr cells in vitro, which is expected to obtain an enough number of induced follicular regulatory T cells, and provides an important tool and a treatment means for in vitro research of immune tolerance related diseases such as autoimmune diseases and organ transplantation.

The present disclosure is directed toward drugs or toxins; drug conjugates comprising said drugs or toxins and a cleavable linker; and conjugates comprising said drugs or toxins, cleavable linkers, and cell-binding groups. The present disclosure also relates to methods of treating cancers, autoimmune diseases, and inflammatory diseases using the compounds and conjugates of the disclosure.

A multi-dimensional body positioning apparatus that can be used in the practice of pilates, yoga, tai chi, and other intelligent movement disciplines, including exercise, rehabilitation, training, physical and mental conditioning, habituation, injury prevention and recovery; in medical protocols for minimizing cascade of disabilities and maximizing muscular and neurological recovery from paralysis, congenital disorders, and auto immune illnesses; and overall healing. The body positioning apparatus includes raised portions that are plateaus that relate to the topology of the human body, which provide visual and tactile references, so the user can properly align the body during exercise or use of the apparatus. By providing these plateaus, the exercise routine can be optimized. For instance, a user can us the apparatus supervised while monitoring proper technique.

The invention discloses a dental ulcer image recognition autoimmune disease blood index correlation analysis system, and relates to the technical field of medical informatics. Comprising a time sequence data acquisition module, a steady state baseline construction module, a cross-modal synchronous analysis module, a deviation degree calculation module, a disease risk judgment module and a risk early warning output module. The system constructs an individualized immune steady-state baseline by acquiring a dental ulcer image of a user and time sequence data of blood indexes related to autoimmunity; the image lesion dynamic evolution rate is used as a guide factor, time extrapolation is carried out on the blood indexes collected asynchronously, and synchronous predictive immune data are generated; by calculating the deviation degree of the prediction data and the steady state baseline, accurate and real-time judgment and early warning of the autoimmune disease risk are realized. According to the invention, the problem of evaluation delay caused by desynchrony of dental ulcer image and blood index acquisition time is effectively solved, and the timeliness and accuracy of health risk monitoring are improved.

Methods of preventing or treating autoimmune disease are disclosed. In some cases, subjects with having or at risk of developing autoimmune disease are identified as possessing one or more autoimmunity-susceptibility HLA alleles at one or more HLA loci. In many cases, the HLA loci are selected from Class I and Class II loci, for example Class I A, B, and C, and Class II DQ, DR, and DP. In many cases, subjects suffering from or at risk of developing an autoimmune disease may be administered a plurality engineered autologous HSCs modified to carry and express a variant susceptibility allele having at least one mutation in the antigen binding cleft that alters antigen binding and / or specificity of that variant HLA molecule. In many embodiments, the engineered HSCs are CD34+ immune cells that express one or more modified HLA proteins.

The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR α chain, TCR β chain, beta-2 microglobulin, a HLA molecule, CTLA-4, PD1, and FAS and further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.

Methods of preventing or treating autoimmune disease are disclosed. In some cases, subjects with having or at risk of developing autoimmune disease are identified as possessing one or more autoimmunity-susceptibility HLA alleles at one or more HLA loci. In many cases, the HLA loci are selected from Class I and Class II loci, for example Class I A, B, and C, and Class II DQ, DR, and DP. In many cases, subjects suffering from or at risk of developing an autoimmune disease may be administered a plurality engineered autologous HSCs modified to carry and express a variant susceptibility allele having at least one mutation in the antigen binding cleft that alters antigen binding and / or specificity of that variant HLA molecule. In many embodiments, the engineered HSCs are CD34+ immune cells that express one or more modified HLA proteins.

The invention provides cold-pressed food suitable for small dogs and a preparation method of the cold-pressed food, and belongs to the field of dog food. The preparation method of the cold-pressed food suitable for the small dogs comprises the following steps: preparing the composite functional microcapsules, preparing granules, and spraying and forming. According to the preparation method of the cold-pressed food suitable for the small dogs, the calcium-phosphorus ratio can be accurately controlled on the premise of ensuring high calcium, and the cold-pressed food is rich in nutrient substances beneficial to normal development and efficient operation of autoimmune systems, cardiovascular systems and liver and kidney systems of the small dogs; the defects that nutritional ingredients are easy to lose efficacy, the particle hardness matching property is poor and the overall stability is poor in the preparation or storage process can be effectively avoided.

The present invention relates to anti-ILT7 antibodies. Antibodies capable of binding to IPC are obtained by using animal cells in which a cell membrane protein that binds to ILT7 is co-expressed as an immunogen. The antibodies of the present invention have high specificity, such that the antibodies can immunologically distinguish ILT7 from other ILT family molecules. The anti-ILT-7 antibodies of the present invention can bind to IPC and inhibit its activity. The activity of IPC can be inhibited by the anti-ILT-7 antibodies of the present invention, and interferon-related diseases can be treated or prevented. In the presence of IFNα, the expression of ILT7 in IPC can still be maintained. Therefore, in patients with various autoimmune diseases with increased IFNα production, an inhibitory effect of anti-ILT-7 antibodies on the activity of IPC can be expected.

Disclosed herein is a method of treating an individual afflicted with moderate to severe ulcerative colitis, the method comprising: administering a local inhibitor of interleukin-23 (IL-23) and tumor necrosis factor alpha (TNF-alpha) to an intestine of the individual.

The invention discloses TCN1 (Trancobalamin 1, cobalamin 1) and application of an inhibitor of the TCN1 in preparation of products for diagnosing and treating diseases of an autoimmune system. According to the invention, expression in psoriasis tissues is up-regulated and promoter DNA methylation is down-regulated into genes to screen TCN1 genes, an over-expression TCN1 HaCaT cell line is constructed, and it is verified that the over-expression TCN1 HaCaT cell line participates in keratinocyte proliferation and IL-17 activation as an autoantigen, can be used as a diagnostic marker and a therapeutic target of autoimmune skin diseases such as psoriasis and the like, and has broad application prospects. And a new direction is provided for mechanism research and treatment of autoimmune skin diseases such as psoriasis.

This disclosure features structurally-stabilized and / or cysteine-reactive peptide inhibitors for selective targeting of BFL-1, or dual targeting of BFL-1 and MCL-1. Also disclosed are methods of using such structurally-stabilized and cysteine-reactive peptides in the treatment of BFL-1- and / or MCL-1-expressing or -dependent cancers or diseases of cellular excess (e.g., autoimmune or inflammatory conditions). Also provided are combination therapies comprising such structurally-stabilized and / or cysteine-reactive peptides and inhibitors of the DNA damage response pathway, such as an ATM kinase inhibitor, ATR kinase inhibitor, CHK1 / 2 inhibitor, or PARP inhibitor; or an inhibitor of MCL-1, or a selective inhibitor of BCL-2, or an inhibitor of BCL-2 / BCL-XL, for the treatment of BFL-1-expressing or -dependent cancers (e.g., AML), BFL-1 and MCL-1-expressing or -dependent cancers, or diseases of cellular excess (e.g., autoimmune or inflammatory conditions).

CD24-positive malignant and benign tumors are treated by administration of a naturally occurring or modified oncolytic Zika virus. Diseases associated with abnormal T cell activation or T cell-mediated autoimmunity, wherein CD24 expression is increased, are also expected to be treated by administration of a naturally occurring or modified oncolytic Zika virus. Also contemplated are compounds and methods for treating and / or preventing Zika virus infection in a subject.

The application discloses application of a small-molecule drug indisulam in preparation of a drug for treating autoimmune diseases, and further verifies safety of the molecule, long-term continuous use of the drug does not cause weight loss of animals, and weight change has no difference with normal control mice; tissue sections of multiple organs show that the drug has no obvious toxic side effects on each organ. In addition, the drug can promote differentiation of regulatory T cells, but does not affect functions of other immune cells. Therefore, the drug is used for treating autoimmune diseases, and good effect is found.

Provided are a compound of formula (I) or a tautomer, enantiomer, diastereomer, isotope-labeled compound, solvate, or pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and use thereof in the preparation of a drug for preventing and treating pyroptosis-related autoimmune diseases, infections, and non-infectious diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to application and a method of PHF20 in preparation of a medicine for treating systemic lupus erythematosus and the medicine. The invention discloses an application of PHF20 in treatment of systemic lupus erythematosus, a lentivirus with murine PHF20 is selected as a gene therapy tool, an R848 induced lupus mouse model is taken as an experimental subject for gene therapy, and results show that injection of the overexpressed PHF20 lentivirus in a lupus mouse body has the following effects: (1) spleen swelling is improved, and spleen index is significantly reduced; (2) reducing urine protein, urea nitrogen level, anti-dsDNA antibody level and IgG antibody level of the model mouse; and (3) the pathological damage to the kidney of the model mouse is relieved. The research results show that the PHF20 serving as the target provides important reference value for potential application prospects in systemic lupus erythematosus gene therapy and even autoimmune disease gene therapy.